Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 1

Status

Completed 2Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 3Tumor-Agnostic 1

Conditions

Endometrial Neoplasms 2Ovarian Neoplasms 1Neoplasms 1Fallopian Tube Neoplasms 1

Interventions

Specimen Handling 273Magnetic Resonance Spectroscopy 224pembrolizumab 214Carboplatin 173Biopsy 166Cisplatin 159Nivolumab 149Cyclophosphamide 133Radiotherapy 117Paclitaxel 117Gemcitabine 112Bevacizumab 92durvalumab 86Dexamethasone 80Rituximab 76Oxaliplatin 73atezolizumab 68Capecitabine 67venetoclax 66Fluorouracil 66Doxorubicin 65Docetaxel 65Etoposide 63Radiosurgery 60Radiation 57Prednisone 57Cytarabine 56Ipilimumab 55Pemetrexed 54Taxes 52

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × rucaparib × 90 days × Clear all
NCT03899155 2026-06-03

Pan Tumor Rollover Study

Bristol-Myers Squibb

Phase 2 Recruiting
1,500 enrolled
Tumor-Agnostic

Neoplasms

NCT03694262 2026-04-13

EndoBARR

Medical College of Wisconsin

Phase 2 Completed
30 enrolled 7 charts
Gynecologic

Endometrial Neoplasms

NCT02873962 2026-04-01

A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
72 enrolled 16 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03617679 2026-03-24

Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer

University of Colorado, Denver

Phase 2 Completed
79 enrolled 12 charts
Gynecologic

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡